Open Access Articles- Top Results for Janus kinase 2

Janus kinase 2

SymbolsJAK2 ; JTK10; THCYT3
External IDsOMIM147796 HomoloGene21033 IUPHAR: 2048 ChEMBL: 2971 GeneCards: JAK2 Gene
EC number2.7.10.2
RefSeq (mRNA)NM_004972NM_001048177
RefSeq (protein)NP_004963NP_001041642
Location (UCSC)Chr 9:
4.99 – 5.13 Mb
Chr 19:
29.25 – 29.31 Mb
PubMed search[1][2]

Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family (IL-3R, IL-5R and GM-CSF-R), the gp130 receptor family (e.g., IL-6R), and the single chain receptors (e.g. Epo-R, Tpo-R, GH-R, PRL-R). JAK2 signaling is activated downstream from the prolactin receptor.[1]

The distinguishing feature between janus kinase 2 and other JAK kinases is the lack of Src homology binding domains (SH2/SH3) and the presence of up to seven JAK homology domains (JH1-JH7). Nonetheless the terminal JH domains retain a high level of homology to tyrosine kinase domains. An interesting note is that only one of these carboxy-terminal JH domains retains its function whilst the other, due to lacking important amino acids for kinase functionality, does not work; it is therefore termed as the pseudokinase domain.[2]

Loss of Jak2 is lethal by embryonic day 12 in mice.[3]

JAK2 orthologs [4] have been identified in all mammals for which complete genome data are available.

Clinical significance

JAK2 gene fusions with the TEL(ETV6) (TEL-JAK2) and PCM1 genes have been found in leukemia patients.[5][6] Jak - 2 kinase mutations were found to have a high correlation with abnormal heart defects in those of Southeast Asian descent carrying the PYFA gene.[5][6] Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, and myelofibrosis as well as other myeloproliferative disorders.[7] This mutation, (V617F) a change of valine to phenylalanine at the 617 position, appears to render hematopoietic cells more sensitive to growth factors such as erythropoietin and thrombopoietin, because the receptors for these growth factors require JAK2 for signal transduction. An inhibitor of JAK2-STAT5, AZD1480, was pointed as having activity in primary and CRPC.[8] Jak2 mutation when demonstratable is one of the methods of diagnosing Polycythemia Rubra Vera.[9]


Janus kinase 2 has been shown to interact with:

Prolactin signals through JAK2 are dependent on STAT5, and on the RUSH transcription factors.[53]

See also


  1. ^ Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998). "Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice". Endocr. Rev. 19 (3): 225–68. PMID 9626554. doi:10.1210/er.19.3.225. 
  2. ^ Morgan KJ, Gilliland DG (2008). "A role for JAK2 mutations in myeloproliferative diseases". Annu. Rev. Med. 59 (1): 213–22. PMID 17919086. doi:10.1146/ 
  3. ^ Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K (1998). "Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis". Cell 93 (3): 397–409. PMID 9590174. doi:10.1016/S0092-8674(00)81168-X. 
  4. ^ "OrthoMaM phylogenetic marker: JAK2 coding sequence". 
  5. ^ a b Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffé M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA (1997). "A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia". Science 278 (5341): 1309–12. PMID 9360930. doi:10.1126/science.278.5341.1309. 
  6. ^ a b Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC (2005). "The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2". Cancer Res. 65 (7): 2662–7. PMID 15805263. doi:10.1158/0008-5472.CAN-04-4263. 
  7. ^ Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N. Engl. J. Med. 352 (17): 1779–90. PMID 15858187. doi:10.1056/NEJMoa051113. 
  8. ^ Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT (October 2013). "Pharmacologic Inhibition of Jak2-Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer". Clin. Cancer Res. 19 (20): 5658–74. PMID 23942095. doi:10.1158/1078-0432.CCR-13-0422. 
  9. ^ Scott LM (2011). "The JAK2 exon 12 mutations: a comprehensive review". Am. J. Hematol. 86 (8): 668–76. PMID 21674578. doi:10.1002/ajh.22063. 
  10. ^ Sarkar S, Pollack BP, Lin KT, Kotenko SV, Cook JR, Lewis A, Pestka S (2001). "hTid-1, a human DnaJ protein, modulates the interferon signaling pathway". J. Biol. Chem. 276 (52): 49034–42. PMID 11679576. doi:10.1074/jbc.M103683200. 
  11. ^ Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999). "ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases". J. Biol. Chem. 274 (24): 17209–18. PMID 10358079. doi:10.1074/jbc.274.24.17209. 
  12. ^ Huang LJ, Constantinescu SN, Lodish HF (2001). "The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor". Mol. Cell 8 (6): 1327–38. PMID 11779507. doi:10.1016/S1097-2765(01)00401-4. 
  13. ^ Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993). "JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin". Cell 74 (2): 227–36. PMID 8343951. doi:10.1016/0092-8674(93)90414-L. 
  14. ^ Sayeski PP, Ali MS, Safavi A, Lyles M, Kim SO, Frank SJ, Bernstein KE (1999). "A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn". J. Biol. Chem. 274 (46): 33131–42. PMID 10551884. doi:10.1074/jbc.274.46.33131. 
  15. ^ Chauhan D, Kharbanda SM, Ogata A, Urashima M, Frank D, Malik N, Kufe DW, Anderson KC (1995). "Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells". J. Exp. Med. 182 (6): 1801–6. PMC 2192257. PMID 7500025. doi:10.1084/jem.182.6.1801. 
  16. ^ Giorgetti-Peraldi S, Peyrade F, Baron V, Van Obberghen E (1995). "Involvement of Janus kinases in the insulin signaling pathway". Eur. J. Biochem. 234 (2): 656–60. PMID 8536716. doi:10.1111/j.1432-1033.1995.656_b.x. 
  17. ^ Frank SJ, Yi W, Zhao Y, Goldsmith JF, Gilliland G, Jiang J, Sakai I, Kraft AS (1995). "Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor". J. Biol. Chem. 270 (24): 14776–85. PMID 7540178. doi:10.1074/jbc.270.24.14776. 
  18. ^ VanderKuur JA, Wang X, Zhang L, Campbell GS, Allevato G, Billestrup N, Norstedt G, Carter-Su C (1994). "Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase". J. Biol. Chem. 269 (34): 21709–17. PMID 8063815. 
  19. ^ Hellgren G, Jansson JO, Carlsson LM, Carlsson B (1999). "The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver". Growth Horm. IGF Res. 9 (3): 212–8. PMID 10502458. doi:10.1054/ghir.1999.0111. 
  20. ^ Gual P, Baron V, Lequoy V, Van Obberghen E (1998). "Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor". Endocrinology 139 (3): 884–93. PMID 9492017. doi:10.1210/endo.139.3.5829. 
  21. ^ Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T (2001). "Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation". J. Exp. Med. 193 (2): 263–9. PMC 2193341. PMID 11208867. doi:10.1084/jem.193.2.263. 
  22. ^ Yamamoto K, Shibata F, Miura O, Kamiyama R, Hirosawa S, Miyasaka N (1999). "Physical interaction between interleukin-12 receptor beta 2 subunit and Jak2 tyrosine kinase: Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor beta 2 via amino-terminus". Biochem. Biophys. Res. Commun. 257 (2): 400–4. PMID 10198225. doi:10.1006/bbrc.1999.0479. 
  23. ^ Ogata N, Kouro T, Yamada A, Koike M, Hanai N, Ishikawa T, Takatsu K (1998). "JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation". Blood 91 (7): 2264–71. PMID 9516124. 
  24. ^ a b c Fuhrer DK, Yang YC (1996). "Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11". Biochem. Biophys. Res. Commun. 224 (2): 289–96. PMID 8702385. doi:10.1006/bbrc.1996.1023. 
  25. ^ Zhu T, Goh EL, Lobie PE (1998). "Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not required for stat-mediated transcription". J. Biol. Chem. 273 (17): 10682–9. PMID 9553131. doi:10.1074/jbc.273.17.10682. 
  26. ^ Ryu H, Lee JH, Kim KS, Jeong SM, Kim PH, Chung HT (2000). "Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin". J. Immunol. 165 (4): 2116–23. PMID 10925297. doi:10.4049/jimmunol.165.4.2116. 
  27. ^ Yin T, Shen R, Feng GS, Yang YC (1997). "Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases". J. Biol. Chem. 272 (2): 1032–7. PMID 8995399. doi:10.1074/jbc.272.2.1032. 
  28. ^ Tauchi T, Damen JE, Toyama K, Feng GS, Broxmeyer HE, Krystal G (1996). "Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis". Blood 87 (11): 4495–501. PMID 8639815. 
  29. ^ Maegawa H, Kashiwagi A, Fujita T, Ugi S, Hasegawa M, Obata T, Nishio Y, Kojima H, Hidaka H, Kikkawa R (1996). "SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates". Biochem. Biophys. Res. Commun. 228 (1): 122–7. PMID 8912646. doi:10.1006/bbrc.1996.1626. 
  30. ^ Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T (1996). "Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1". Mol. Cell. Biol. 16 (12): 6985–92. PMC 231702. PMID 8943354. 
  31. ^ Wu DW, Stark KC, Dunnington D, Dillon SB, Yi T, Jones C, Pelus LM (2000). "SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells". Blood Cells Mol. Dis. 26 (1): 15–24. PMID 10772872. doi:10.1006/bcmd.2000.0273. 
  32. ^ Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL, Pestka S (1999). "The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity". J. Biol. Chem. 274 (44): 31531–42. PMID 10531356. doi:10.1074/jbc.274.44.31531. 
  33. ^ Rui L, Mathews LS, Hotta K, Gustafson TA, Carter-Su C (1997). "Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling". Mol. Cell. Biol. 17 (11): 6633–44. PMC 232517. PMID 9343427. 
  34. ^ Xie S, Lin H, Sun T, Arlinghaus RB (2002). "Jak2 is involved in c-Myc induction by Bcr-Abl". Oncogene 21 (47): 7137–46. PMID 12370803. doi:10.1038/sj.onc.1205942. 
  35. ^ VanderKuur J, Allevato G, Billestrup N, Norstedt G, Carter-Su C (1995). "Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2". J. Biol. Chem. 270 (13): 7587–93. PMID 7535773. doi:10.1074/jbc.270.13.7587. 
  36. ^ Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L, Delmastro P, Gadina M, Scala G (1997). "Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase". J. Immunol. 158 (9): 4097–103. PMID 9126968. 
  37. ^ Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A (2000). "CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2". J. Biol. Chem. 275 (38): 29338–47. PMID 10882725. doi:10.1074/jbc.M003456200. 
  38. ^ Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A (1999). "Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain". Genes Cells 4 (6): 339–51. PMID 10421843. doi:10.1046/j.1365-2443.1999.00263.x. 
  39. ^ a b Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A (1997). "Cloning and characterization of novel CIS family genes". Biochem. Biophys. Res. Commun. 239 (2): 439–46. PMID 9344848. doi:10.1006/bbrc.1997.7484. 
  40. ^ a b Barahmand-Pour F, Meinke A, Groner B, Decker T (1998). "Jak2-Stat5 interactions analyzed in yeast". J. Biol. Chem. 273 (20): 12567–75. PMID 9575217. doi:10.1074/jbc.273.20.12567. 
  41. ^ a b Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T (1997). "An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT". Oncogene 14 (7): 751–61. PMID 9047382. doi:10.1038/sj.onc.1200907. 
  42. ^ Takeshita T, Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K (1997). "STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction". Immunity 6 (4): 449–57. PMID 9133424. doi:10.1016/S1074-7613(00)80288-5. 
  43. ^ Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A (1999). "The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop". EMBO J. 18 (5): 1309–20. PMC 1171221. PMID 10064597. doi:10.1093/emboj/18.5.1309. 
  44. ^ Dif F, Saunier E, Demeneix B, Kelly PA, Edery M (2001). "Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor". Endocrinology 142 (12): 5286–93. PMID 11713228. doi:10.1210/endo.142.12.8549. 
  45. ^ Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A (1997). "A new protein containing an SH2 domain that inhibits JAK kinases". Nature 387 (6636): 921–4. PMID 9202126. doi:10.1038/43213. 
  46. ^ Pezet A, Favre H, Kelly PA, Edery M (1999). "Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling". J. Biol. Chem. 274 (35): 24497–502. PMID 10455112. doi:10.1074/jbc.274.35.24497. 
  47. ^ Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O (2002). "Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1". Mol. Cell. Biol. 22 (10): 3316–26. PMC 133778. PMID 11971965. doi:10.1128/MCB.22.10.3316-3326.2002. 
  48. ^ Takahashi-Tezuka M, Hibi M, Fujitani Y, Fukada T, Yamaguchi T, Hirano T (1997). "Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK". Oncogene 14 (19): 2273–82. PMID 9178903. doi:10.1038/sj.onc.1201071. 
  49. ^ Yamashita Y, Watanabe S, Miyazato A, Ohya Ki, Ikeda U, Shimada K, Komatsu N, Hatake K, Miura Y, Ozawa K, Mano H (1998). "Tec and Jak2 kinases cooperate to mediate cytokine-driven activation of c-fos transcription". Blood 91 (5): 1496–507. PMID 9473212. 
  50. ^ Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB (1998). "Induction of Jak/STAT signaling by activation of the type 1 TNF receptor". J. Immunol. 160 (6): 2742–50. PMID 9510175. 
  51. ^ Shigematsu H, Iwasaki H, Otsuka T, Ohno Y, Arima F, Niho Y (1997). "Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity". J. Biol. Chem. 272 (22): 14334–40. PMID 9162069. doi:10.1074/jbc.272.22.14334. 
  52. ^ "Findings of scientific misconduct". NIH Guide Grants Contracts 24 (42): 1–2. 1995. PMID 7495607. 
  53. ^ Helmer RA, Panchoo M, Dertien JS, Bhakta SM, Hewetson A, Chilton BS (August 2010). "Prolactin-induced Jak2 phosphorylation of RUSH: a key element in Jak/RUSH signaling". Mol. Cell. Endocrinol. 325 (1-2): 143–9. PMC 2902710. PMID 20562009. doi:10.1016/j.mce.2010.05.010. 

Further reading

  • Berger R (2006). "[A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders]". Pathol. Biol. 54 (4): 182–4. PMID 16084028. doi:10.1016/j.patbio.2005.07.002. 
  • Pargade V, Darnige L, Gaussem P (2006). "[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera]". Ann. Biol. Clin. (Paris) 64 (1): 3–9. PMID 16420986. 
  • Staerk J; Kallin A; Royer Y et al. (2007). "JAK2, the JAK2 V617F mutant and cytokine receptors". Pathol. Biol. 55 (2): 88–91. PMID 16904848. doi:10.1016/j.patbio.2006.06.003. 
  • Hsu HC (2007). "Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders". Journal of the Chinese Medical Association : JCMA 70 (3): 89–93. PMID 17389152. doi:10.1016/S1726-4901(09)70337-5. 

External links